Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/jac/dkaa272 http://scihub22266oqcxt.onion/10.1093/jac/dkaa272 32591771!7337743!32591771     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Antimicrob+Chemother 2020 ; 75 (9): 2381-2383 Nephropedia Template TP {{tp|p=32591771|t=2020. The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics |pdf=|usr=}}{{32591771}} gab.com Text The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics JO: J Antimicrob Chemother http://www.kidney.de/pget.php?&tw=1&pmid=32591771 #FOAvip The development of therapeutic agents against SARS-CoV-2/COVID-19 faces numerous barriers and a multidisciplinary approach to evaluating drug efficacy and toxicity is essential. Experimental and preclinical data should be integrated into a comprehensive analysis, where drug potency, the timing of therapy initiation, drug combinations, variability in systemic and local drug exposure and short- and long-term toxicities represent fundamental factors for the rational identification of candidates and prioritization of clinical investigations. Although the identification of SARS-CoV-2 therapeutics is a priority, rigorous and transparent methodologies are crucial to ensure that accelerated research programmes result in high-quality and reproducible findings. Twit Text FOAVip The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics ????J Antimicrob Chemother http://www.kidney.de/pget.php?&tw=1&pmid=32591771 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32591771 #FOAvip English Wikipedia <ref>{{Cite pmid|32591771}}</ref> The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics #MMPMID32591771 Siccardi M; Schapiro J; Di Perri G; Back DJ J Antimicrob Chemother 2020[Sep]; 75 (9): 2381-2383 PMID32591771show ga The development of therapeutic agents against SARS-CoV-2/COVID-19 faces numerous barriers and a multidisciplinary approach to evaluating drug efficacy and toxicity is essential. Experimental and preclinical data should be integrated into a comprehensive analysis, where drug potency, the timing of therapy initiation, drug combinations, variability in systemic and local drug exposure and short- and long-term toxicities represent fundamental factors for the rational identification of candidates and prioritization of clinical investigations. Although the identification of SARS-CoV-2 therapeutics is a priority, rigorous and transparent methodologies are crucial to ensure that accelerated research programmes result in high-quality and reproducible findings. |*Betacoronavirus[MESH] |Animals[MESH] |Antibodies, Viral/blood/*drug effects[MESH] |Antiviral Agents/pharmacology/*therapeutic use[MESH] |COVID-19[MESH] |Coronavirus Infections/blood/diagnosis/*drug therapy[MESH] |Drug Discovery/methods/*trends[MESH] |Humans[MESH] |Pandemics[MESH] |Pneumonia, Viral/blood/diagnosis/*drug therapy[MESH]The challenging pathway towards the identification of SARS-CoV-2/COVID(epmc).pdf DeepDyve Pubget Overpricing